Tasly Biopharmaceuticals Co., Ltd.

Quick facts

Phase 3 pipeline

• Aspirin simulation agent · Cardiovascular
  An aspirin simulation agent mimics the antiplatelet and anti-inflammatory effects of aspirin through a novel mechanism or formulation approach.
• Recombinant human urokinase · Cardiovascular
  Recombinant human urokinase is a thrombolytic agent that works by activating plasminogen to plasmin, which then breaks down blood clots.
• rhPro-UK · Oncology
  rhPro-UK is a recombinant human prokineticin-2 analogue that acts as a prokineticin-2 receptor agonist.
• rhPro-UK simulation agent · Cardiovascular / Thrombosis
  rhPro-UK is a recombinant human prourokinase that converts plasminogen to plasmin to dissolve blood clots.

Phase 2 pipeline

• B1962 · Diabetes
  B1962 is a small molecule that targets the SGLT2 receptor.
• Recombinant Human Prourokinase

Phase 1 pipeline

• B1344

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tasly Biopharmaceuticals Co., Ltd. portfolio CI brief
• Tasly Biopharmaceuticals Co., Ltd. pipeline updates RSS